Q-omics provides the consensus-scored CDV3P1 profile across patient tissues and cancer cell-line models. CDV3P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CDV3P1 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, CDV3P1 RNA expression shows 5,276 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, COAD, and STAD as cancer lineages where CDV3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDV3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDV3P1 survival associations across molecular data types. CDV3P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDV3P1 RNA expression–survival associations across cancer types. High CDV3P1 expression shows unfavorable associations in DLBC, CESC, CHOL, MESO and ACC, but favorable associations in SKCM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for CDV3P1 RNA expression.
This table summarizes CDV3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CDV3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDV3P1 shows higher tumor expression in COAD. The COAD box plot shows higher CDV3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p = .032).
This table shows molecular features associated with CDV3P1 in patient tissues and cancer cell lines. In patient samples, CDV3P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
